3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Terminated
1
Not yet recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Dermatologic
1
Conditions
Melanoma
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Nivolumab
17
Ipilimumab
14
pembrolizumab
11
Cyclophosphamide
8
trametinib
7
dabrafenib
6
Interleukin-2
6
aldesleukin
5
Vemurafenib
5
Radiotherapy
5
sargramostim
4
130-nm albumin-bound paclitaxel
4
fludarabine
3
encorafenib
3
binimetinib
3
Specimen Handling
3
Radiosurgery
3
Melphalan
3
Granulocyte-Macrophage Colony-Stimulating Factor
3
fludarabine phosphate
2
Magnetic Resonance Spectroscopy
2
Introns
2
Infliximab
2
Celecoxib
2
CTLA-4 Antigen
2
Biopsy
2
Bevacizumab
2
Albumin-Bound Paclitaxel
2
yeast-CEA vaccine
1
vitespin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Melanoma
×
vedolizumab
×
Clear all
NCT06646016
2025-12-26
EPIC
Therakos LLC
Phase 2
Withdrawn